---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-039171"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:59:01.059017+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biofrontera raises $4.5M in registered direct offering, amends existing warrants to $3.55

## Summary
- Gross proceeds of ~$4.5M from sale of 1,205,000 shares/pre-funded warrants and 1,807,500 common warrants.
- Common warrants exercisable at $3.55/share, expire 5 years from issuance; pre-funded warrants at $0.0001.
- Existing warrants for 385,236 shares amended to $3.55 exercise price and extended to November 2, 2028.
- Roth Capital Partners acted as placement agent; cash fee of 7% of gross proceeds plus expenses.
- Net proceeds to be used for working capital and general corporate purposes.

## SEC filing metadata
- accession: 0001493152-23-039171
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315223039171/0001493152-23-039171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315223039171/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-039171
- JSON: https://secwatch.observer/filing/0001493152-23-039171.json
- Plain text: https://secwatch.observer/filing/0001493152-23-039171.txt

## Key facts
- Material Agreements
  Biofrontera Inc. amended Existing Warrants Amendment with an institutional investor valued at Amendment to revise exercise price to $3.55 and extend expiration date to November 2, 2028 (effective 2023-10-30).
  - Action: amendment
  - Counterparty: an institutional investor
  - Value: Amendment to revise exercise price to $3.55 and extend expiration date to November 2, 2028
  - Effective: 2023-10-30
  source text: On October 30, 2023, in connection with the Purchase Agreement, the Company entered into an amendment to the Existing Warrants (the “ Existing Warrants Amendment ”) pursuant to which the Company agreed, effective November 2, 2023, to (i) revise the exercise price of the Existing Warrants to $3.55 and (ii) extend the date until which the Existing Warrants can be exercised until November 2, 2028.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315223039171/0001493152-23-039171-index.htm
- Material Agreements
  Biofrontera Inc. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at Gross proceeds of approximately $4.5 million from sale of 1,205,000 shares of common stock and warra (effective 2023-10-30).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Roth Capital Partners, LLC
  - Value: Gross proceeds of approximately $4.5 million from sale of 1,205,000 shares of common stock and warra
  - Effective: 2023-10-30
  source text: On October 30, 2023, Biofrontera Inc., a Delaware corporation (the “Company”), entered into a placement agency agreement (the “ Placement Agency Agreement ”) with Roth Capital Partners, LLC (the “ Placement Agent ”) and a securities purchase agreement (the “ Purchase Agreement ”) with an institutional investor for the purchase and sale, in a registered public offering by the Company (the “ Public Offering ”) of an aggregate of 1,205,000 shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), or pre-funded warrants to purchase Common Stock in lieu thereof, each of which is coupled with a warrant to purchase one and one-half shares of Common Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315223039171/0001493152-23-039171-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.